1 / 18

DNA Repair Drugs Market Analysis (2018-2026)

Read here the market research report on the u201cDNA Repair Drugs Market" published by CMI Team

kunalbhuta
Télécharger la présentation

DNA Repair Drugs Market Analysis (2018-2026)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Coherent Market Insights Market Research and Business Consulting Services https://www.coherentmarketinsights.com/ COVID-19 Impact Tracker

  2. DNA REPAIR DRUGS MARKET ANALYSIS - (2018-2026) • DNA Repair Drugs Market, by Drug (Niraparib (Zejula), Olaparib (Lynparza), Rucaparib (Rubraca), Talazoparib(Talzenna), and Others), by Application (Ovarian cancer, Fallopian Tube cancer, Peritoneal cancer, Breast cancer and Gastric cancer) by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026

  3. DNA repair drugs such as Niraparib (Zejula), Olaparib (Lynparza), Rucaparib (Rubraca), and Talazoparib (Talzenna) are used for treating ovarian and breast cancer. These drugs fall under the category of Poly ADP-ribose Polymerase (PARP) inhibitors used as monotherapy in combination with other drugs for treatment of cancer.

  4. Market Dynamics • Increasing incidences of cancer, increasing collaboration and acquisition with product launch by market players are major factors driving global DNA repair drugs market growth. In May 2019, AstraZeneca and Merck received the Health Canada approval for Lynparza as monotherapy maintenance treatment for patients with advanced high-grade epithelial ovarian cancer, fallopian tube or primary peritoneal cancer. • Furthermore, inorganic strategies adopted by key players to enhance their product portfolio is expected to drive the market growth. In May 2019, Clovis Oncology, Inc., in collaboration with Bristol-Myers Squibb Company and Foundation Medicine Inc., initiated Phase II trials to evaluate rucaparib in combination with nivolumab in patients with high-grade serous carcinoma (HGSC) or endometrioid ovarian cancer.

  5. Key features of the study: • This report provides in-depth analysis of DNA repair drugs market and provides market size (US$ million) and compound annual growth rate (CAGR %) over the forecast period (2018–2026), considering 2017 as the base year • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players • It profiles key players in the global DNA repair drugs market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans

  6. Key companies covered as a part of this study include AstraZeneca Plc., Johnson & Johnson, GlaxoSmithKline plc., Pfizer, Inc., Clovis Oncology Inc., AbbVie Inc., Bristol - Myers Squibb, Merck KGaA, Genentech, Inc., Repare Therapeutics Inc., Karyopharm Therapeutics Inc., Ono Pharmaceutical Co., LTD., and Jiangsu Hengrui Medicine Co., Ltd. • Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics • The global DNA repair drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global DNA repair drugs market

  7.  Detailed Segmentation: • Global DNA Repair Drugs Market, By Drug Type: • Niraparib (Zejula) • Olaparib (Lynparza) • Rucaparib (Rubraca) • Talazoparib (Talzenna) • Global DNA Repair Drugs Market, By Application: • Ovarian Cancer • Breast Cancer

  8. Global DNA Repair Drugs Market, By Distribution Channel: • Hospital Pharmacies • Retail Pharmacies • Online Pharmacies

  9. Global DNA Repair Drugs Market, By Region: • By Distribution Channel: • Hospital Pharmacies • Retail Pharmacies • Online Pharmacies • By Country: • U.S. • Canada • North America • By Drug Type: • Niraparib (Zejula) • Olaparib (Lynparza) • Rucaparib (Rubraca) • Talazoparib (Talzenna) • By Application: • Ovarian Cancer • Breast Cancer

  10. By Distribution Channel: • Hospital Pharmacies • Retail Pharmacies • Online Pharmacies • By Country: • Brazil • Mexico • Argentina • Rest of Latin America • Latin America • By Drug Type: • Niraparib (Zejula) • Olaparib (Lynparza) • Rucaparib (Rubraca) • Talazoparib (Talzenna) • By Application: • Ovarian Cancer • Breast Cancer

  11. By Distribution Channel: • Hospital Pharmacies • Retail Pharmacies • Online Pharmacies • By Country: • Germany • U.K. • France • Italy • Spain • Russia • Rest of Europe • Europe • By Drug Type: • Niraparib (Zejula) • Olaparib (Lynparza) • Rucaparib (Rubraca) • Talazoparib (Talzenna) • By Application: • Ovarian Cancer • Breast Cancer

  12. By Country: • China • India • Japan • Australia • South Korea • ASEAN • Rest of Asia Pacific • Middle East • By Drug Type: • Niraparib (Zejula) • Olaparib (Lynparza) • Rucaparib (Rubraca) • Talazoparib (Talzenna) • Asia Pacific • By Drug Type: • Niraparib (Zejula) • Olaparib (Lynparza) • Rucaparib (Rubraca) • Talazoparib (Talzenna) • By Application: • Ovarian Cancer • Breast Cancer • By Distribution Channel: • Hospital Pharmacies • Retail Pharmacies • Online Pharmacies

  13. Johnson & Johnson • GlaxoSmithKline plc. • Pfizer, Inc. • Clovis Oncology Inc. • AbbVie Inc. • Bristol Myers Squibb • Merck KGaA • By Country/Region: • South Africa • Central Africa • North Africa • Company Profiles • AstraZeneca Plc.* • Company Overview • Product Portfolio • Financial Performance • Key Highlights • Market Strategies

  14. Genentech, Inc. • Artios Pharma • Repare Therapeutics Inc. • Sierra Oncology, Inc. • Karyopharm Therapeutics Inc. • Ono Pharmaceutical Co., Ltd. • Jiangsu Hengrui Medicine Co., Ltd. •  “*” marked represents similar segmentation in other categories in the respective section.

  15. Request Sample Report • Request Customization • Download PDF Brochure • Talk to Analyst • Buy Now Reference:https://www.coherentmarketinsights.com/market-insight/dna-repair-drugs-market-2617

  16. About Us Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. What we provide: • Customized Market Research Services • Industry Analysis Services • Business Consulting Services • Market Intelligence Services • Long term Engagement Model • Country Specific Analysis

  17. Contact Us Mr. Shah Coherent Market Insights Pvt.Ltd. Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S. Phone: +1-206-701-6702 Email: sales@coherentmarketinsights.com

  18. Thank You! Kindly follow CMI Social Media Profiles for the latest company updates Facebook Linkedin Twitter https://www.coherentmarketinsights.com/

More Related